University of Patras
Analysis of the mechanisms of function of T-cell products in cellular immunotherapy
Abstract
dc:descriptionAllogeneic haematopoietic cell tranplantation (Allo-HCT) has become a standard treatment for patients with marrow failure syndromes and hematologic malignancies such as acute leukaemia. However, this treatment is frequently accompanied by the occurrence of Graft-versus-Host Disease (GvHD), a common life-threatening complication in which donor-derived T cells recognise and attack the host’s normal tissues. This phenomenon can occur either early (aGvHD) or later (cGvHD) following allo-HCT and can transpire even when aggressive immunosuppressive prophylaxis is given or even when the donor is an HLA-matched sibling. Despite ground-breaking discoveries in GvHD pathobiology and advances in our understanding of the underlying mechanisms of this disease, conventional immunosuppressive pharmacotherapy remains the backbone of GvHD prophylaxis and treatment. A promising alternative strategy against GvHD is immunotherapy employing the adoptive transfer of T-cells with regulatory properties (Tregs) as a living drug aiming to avoid prolonged pharmacological immunosuppression while preserving the beneficial Graft-versus-Leukaemia effect. Our approach aspired to mimic the physiological mechanism of the successful immune tolerance transpiring during pregnancy, where HLA-G -a well-known immunoregulatory molecule- is expressed in the placenta thereby guarding the “semi-allogeneic” fetus from maternal immune rejection. Since the HLA-G gene is epigenetically repressed after prenatal life and the methylation status of HLA-G promoter regulates its transcriptional activity, we showed in small-scale in vitro experiments that exposure of human peripheral T cells to hypomethylating agents (Has) induces a de novo and stable expression of HLA-G, in turn, converting them to Tregs with in vitro immunosuppressive functions. Subsequently, we developed and validated the manufacturing process of a HLA-G+ T cell (G+ cell)-enriched product, termed iG-Tregs, using a clinical scale and GMP-grade protocol. iG-Tregs can be consistently and robustly produced and display suppressive properties with a favourable safety profile both in vitro and in vivo. The current thesis plays a pivotal part in the translation journey of iG-Tregs as it focuses on elucidating the molecular aspects of G+ cell biology, the design of an interventional clinical trial to translate iG-Tregs as adoptive cell immunotherapy in the context of GvHD post allo-HCT and finally to provide a framework upon which to gain insight into the biological events occurring following this treatment in the human in vivo setting.
Degree
thesis:*- Grantor dc:publisher
- University of Patras
- Year dc:date
- 2024
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Lysandrou, Memnon
- Λυσάνδρου, Μέμνων
Subjects
dc:subject × 14- Υιοθετούμενη κυτταρική ανοσοθεραπεία
- Ρυθμιστικά Τ λεμφοκύτταρα
- Αλλογενής μεταμόσχευση αιμοποιητικών κυττάρων
- Νόσος μοσχεύματος έναντι του ξενιστή
- Adoptive cell immunotherapy
- Regulatory T cells
- Allogeneic hemopoietic stem cell transplantation
- Graft versus host disease
- Άλλες Ιατρικές Επιστήμες
- Ιατρική και Επιστήμες Υγείας
- Ιατρική έρευνα και Πειραματική ιατρική
- Other Medical Sciences
- Medical and Health Sciences
- Research and Experimental medicine
Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/55962